Immune and metabolic pathways of microbial population structure remodeling in biopharmaceuticals for intestinal diseases

Gut microorganisms have become a hot spot of scientific research at home and abroad in recent years, in which the study of correlation between microbial community structure and intestinal diseases can provide theoretical basis for biopharmaceuticals for intestinal diseases. In this paper, we constructed in vitro simulated gastric and small intestinal digestion models, as well as large intestinal microbial fermentation models, to study the relative molecular weight and spatial structure changes of β-glucan in simulated gastric and small intestinal regions, and investigated the degradation of β-glucan in simulated large intestinal regions as well as its effects on intestinal microorganisms. In addition to the biochemical and metabolic aspects, integrating biomechanical principles into this research can enhance our understanding of how gut microbes interact with the host’s physiological environment. For instance, the biomechanical properties of the gut—such as motility, peristalsis, and the mechanical forces exerted on microbial populations—can influence the distribution and activity of gut microorganisms. Understanding these biomechanical factors may reveal how they affect the degradation of β-glucan and the overall microbial community structure. Secondly, fecal microorganisms from different batches of mice and different individuals of human volunteers were collected as inoculum for fermentation of β-glucan, to analyze the main microorganisms that stably responded to β-glucan in different batches of fermentation experiments as well as in gut microorganisms from different individuals and to further investigate the metabolic changes, metabolic pathways as well as the biomarkers of β-glucan in the simulated large intestine. L. murinus Mic06, L. murinus Mic07, L. murinus Mic08, and L. murinus Mic094 were validated to be able to utilize β-glucan and produce a small amount of reducing sugars in all four species of Lactobacillus intestinalis in mice, and there was no significant difference in the ability to utilize them; All nine species of human enterobacteriophages were able to utilize β-glucan and produce reducing sugars, with B. xylanisolvens Bac02 and B. koreensis Bac08 having a significantly greater ability to utilize β-glucan. This study contributes to a deeper understanding of gut disease-associated flora and provides strong support for the use of the gut microbiome for multidisease classification. Additionally, considering biomechanical aspects may lead to novel insights into the interactions between gut microbes and host physiology, enhancing the development of targeted biopharmaceuticals.